Soligenix is a clinical-stage company developing dusquetide (SGX945) for ulcers in Behçet's disease, synthetic hypericin (SGX302) for psoriasis and heat-stabilized vaccines; none are approved.
Soligenix was built around HyBryte, which it ended in June 2026 after the data monitoring committee recommended stopping the confirmatory Phase 3 FLASH2 for futility. What remains is early, led by dusquetide (SGX945), which met its Phase 2a primary endpoint in oral ulcers of Behçet's disease. Cash was $9.8 million at June 30, and Soligenix reports substantial doubt about continuing as a going concern and is exploring strategic alternatives, including a merger.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: A strategic transaction gives Soligenix a path forward
Does Soligenix complete a transaction that gives shareholders a funded program?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
After HyBryte's Phase 3 was stopped for futility, Soligenix is weighing strategic options with cash it says lasts into Q2 2028
SGX945 carries Soligenix after SGX301's Phase 3 failure, but $6M cash and pre-Phase 2b status make survival to proof-of-concept the defining question
FDA Grants Orphan Drug Designation for SGX945 in Behçet's Disease
SGX945 Phase 2a Primary Endpoint Met in Behçet's Disease
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Infectious diseases, Skin diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
3 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.